Selected references
- San-Miguel J, Harousseau JL, Joshua D, Anderson KC. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol. 2008;26(16):2761–6.
- Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al.. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet. 2010;376:2075–85.
- Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al.. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial. Lancet Oncol. 2010;11:9–37.
- San Miguel J, Schlag R, Khuageva N, et al.. A phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with Melphalan-Prednisone (MP) in newly diagnosed multiple myeloma. N Engl J Med. 2008;359(9):906–17.
- Stewart K, Richardson P, San Miguel J. How I treat multiple myeloma in younger patients. Blood. 2009;114(27):5436–43.
- Ludwig H, Bolejack V, Crowley J. Bladé J, Miguel JS, Kyle RA, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010;28(9):1599–605.
- Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA, et al.. International Myeloma Working Group consensus statement regarding the current status of allogeneic transplantation for multiple myeloma. J Clin Oncol. 2010;28(29):4521–30.
- Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al.. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495–502.
- Lahuerta JJ, Mateos MV, Martines-Lopez J, Rosiñol L, Sureda A, de la Rubia J, et al.. Influence of pre-and post transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26(35):5775–82.
- Paiva B, Vidriales MB, Mateo G, Pérez JJ, Montalbán MA, Sureda A, et al.. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognosis subgroup of symptomatic multiple myeloma patients. Blood. 2009;114(20):4369–72.